• 한국동물위생학회지
• /
• 제37권2호
• /
• pp.97-100
• /
• 2014

This study was performed in Korea to get serological information for bovine herpesvirus 1 (BoHV-1), most commonly found in cattle. Antibodies against BoHV-1 were examined by targeting infectious bovine rhinotracheitis (IBR) in unvaccinated and vaccinated cattle, using viral neutralization (VN) test. In 2013, among 261 sera collected from IBR-unvaccinated herds, 7 sera (2.7%) were found seropositive and their VN titers were ranging from 1:4 to 1:32. Among 315 sera collected from IBR-vaccinated herds in large capacity farms, 303 sera (96.2%) were found to be seropositive for BoHV-1 and their VN titers were in the range of 1:4 to 1:2048. It was found that the IBR-vaccinated herds had higher levels of VN titer than IBR-unvaccinated herds. The results indicated that it may be due to heavy vaccination in vaccinated herds and no or a little infection in unvaccinated herds. At the end of the study it was concluded that although the seropositivity in IBR-unvaccinated herds was low, the monitoring of IBR should be continuously practiced to control and prevent the disease because of exportation of living cattle causing its nationwide outbreaks.

• 한국미생물학회:학술대회논문집
• /
• 한국미생물학회 1998년도 제38회 춘계학술발표대회
• /
• pp.39.1-39.1
• /
• 1998

• 미생물학회지
• /
• 제44권1호
• /
• pp.14-21
• /
• 2008

소의 혈액, 세포, 조직, 기관 등은 생물의약품과 조직공학제제, 세포치료제의 원료로 널리 사용되고 있다. 소유래 물질을 원료로 사용한 제제의 경우 소유래 원료 물질에 다양한 바이러스가 오염된 사례가 있기 때문에 바이러스 안전성 검증이 필수적이다. Bovine herpesvirus type 1 (BHV-1)은 소에게 가장 흔하게 감염되는 바이러스중의 하나이다. 소유래 물질을 원료로 하는 생물의약품, 조직공학제제, 세포치료제 등에서 BHV-1안전성을 확보하기 위해, 원료물질, 제조공정, 완제품에서 BHV-1을 정량적으로 검출하고, 제조공정에서 BHV-1 제거 검증을 위한 시험법으로 활용이 가능한 BHV-1 real-time PCR 시험법을 확립하였다. BHV-1에 특이적인 primer를 선별하였으며, 형광염료 SYBR Green I을 사용하여 BHV-1 DNA 정량 검출 시험법을 최적화하였다. 세포배양법에 의한 감염역가와 비교한 결과 real-time PCR 민감도는 $2\;TCID_{50}/ml$이었다. 확립된 시험법의 신뢰성(reliability)을 보증하기 위해 시험법 검증을 실시한 결과 특이성(specificity)과 재현성(reproducibility)이 우수함을 확인하였다. 확립된 real-time PCR을 생물의약품 제조공정 검증에 적용할 수 있는지 확인하기 위하여 인위적으로 BHV-1을 오염시킨 Chinese hamster ovary (CHO) 세포주와 소유래 콜라겐에서 BHV-1 검출 시험을 실시하였다. BHV-1을 감염시킨 CHO 세포에서 세포변병효과를 관찰할 수 없었지만, 세포와 세포배양 상청액에서 BHV-1을 정량적으로 검출할 수 있었다. 소유래 콜라겐에서도 $10\;TCID_{50}/ml$까지 정량적으로 검출할 수 있었다. 위와 같은 결과에서 확립된 BHV-1 real-time PCR 시험법은 생물의약품 안전성 보증을 위한 세포주 검증, 생물의약품생산공정 검증, 바이러스 제거 공정 검증 등에서 감염역가 시험법과 같은 생물학적 시험법을 대신할 수 있는 신속하고, 특이성과 민감성이 우수한 시험법임을 확인하였다.

• 대한바이러스학회지
• /
• 제26권2호
• /
• pp.173-179
• /
• 1996

The gene encoding gIII of bovine herpesvirus type 1 (BHV-1) PQ strain was cloned and expressed in baculovirus. Although the gIII gene is located in Hind III I fragment as the case of the other BHV-1 strains, differences in size and restriction endonuclease site within the fragment were identified. The gIII expression was predominantly detected on the surface on insect cells by indirect immunofluoresecnce assay using monoclonal antibody. The western blotting analysis also revealed the presence of expressed protein of a similar molecular size to the original gIII protein. The immunogenicity of expressed protein were tested in guinea pigs. The immunized guinea pigs with expressed protein developed the neutralizing antibodies against BHV-1.

• Journal of Veterinary Science
• /
• 제21권5호
• /
• pp.72.1-72.10
• /
• 2020

Background: Fenbendazole, a dewormer drug, is used widely in the clinical treatment of parasite infections in animals. Recent studies have shown that fenbendazole has substantial effects on tumor growth, immune responses, and inflammatory responses, suggesting that fenbendazole is a pluripotent drug. Nevertheless, the antiviral effects have not been reported. Fenbendazole can disrupt microtubules, which are essential for multiple viruses infections, suggesting that fenbendazole might have antiviral effects. Objectives: This study examined whether fenbendazole could inhibit bovine herpesvirus 1 (BoHV-1) productive infection in cell cultures. Methods: The effects of fenbendazole on viral production, transcription of the immediate early (IE) genes, viron-associated protein expression, and the cellular signaling PLC-γ1/Akt pathway were assessed using distinct methods. Results: Fenbendazole could inhibit BoHV-1 productive infections significantly in MDBK cells in a dose-dependent manner. A time-of-addition assay indicated that fenbendazole affected both the early and late stages in the virus replication cycles. The transcription of IE genes, including BoHV-1 infected cell protein 0 (bICP0), bICP4, and bICP22, as well as the synthesis of viron-associated proteins, were disrupted differentially by the fenbendazole treatment. The treatment did not affect the cellular signaling pathway of PLC-γ1/Akt, a known cascade playing important roles in virus infection. Conclusions: Overall, fenbendazole has antiviral effects on BoHV-1 replication.

• BMB Reports
• /
• 제31권4호
• /
• pp.355-363
• /
• 1998

MHC unrestricted, antigen nonspecific killing by $CD4^+$ T-cells against virally-infected target cells was induced following cross-linking of CD4 molecules. The cytotoxicity of antibody-activated $CD4^+$ T-cells was abolished by genistein (4',5,7-trihydroxyisoflavone), a protein tyrosine kinase (PTK) inhibitor, but not by H-7, a protein kinase C (PKC) inhibitor. Genisteintreated human or bovine peripheral blood $CD4^+$ T-cells lacked PTK activity and failed to kill virally-infected target cells even after cross-linking of CD4 molecules. The cross-linking of CD4 molecules did not induce effector cell proliferation or the transcription of TNF ${\beta}$. TNF ${\beta}$ synthesis was up-regulated by incubating antibody activated effector cells with bovine herpesvirus type 1 (BHV-1) infected D17 target cells. Anti-TNF ${\beta}$ antibody partially abrogated direct effector cell-mediated antiviral cytotoxicity. On the other hand, this antibody effectively neutralized antiviral activity of effector and target cell culture supernatants against BHV-1 infected D17 cells. The inhibition level of the antiviral activity by the antibody was dependent on effector and target cell ratio. These findings have importance to define the mechanisms of how CD4 cytotoxic cells control viral infection.

• 농업과학연구
• /
• 제14권2호
• /
• pp.401-408
• /
• 1987

세포융합기술(細胞融合技術)을 이용하여 소전염성비기관염(傳染性鼻氣管炎)바이러스(IBRV) 항원(抗原)에 대응(對應)하는 9주(株) 단(單)클론성항체(性抗體)를 생산하였으며, 이들 항체(抗體)의 특성(特性)을 형광항체법(螢光抗體法), 혈청중화시험(血淸中和試驗) 및 전기영동분석법(電氣泳動分析法)으로 시험(試驗)하였다. 생산된 2종(種)의 단(單)클론성 항체(抗體)중 8종(種)은 IBRV이외의 Pseudorabies virus, Infectious laryngotracheitis virus, Marek's disease virus, Japanese B encephalitis virus, Porcine parvovirus, Transmissible gastroenteritis virus, Hogcholera virus와 교차반응(交叉反應)이 없는 특이항체(特異抗體)였으나 1종(種)은 Pseudorabies virus와 교차(交叉)하는 항체(抗體)였다. 이들 단(單)클론성 항체중 중화능력(中和能力)이 있는 2주(株)는 IBRV 항원단백(抗原蛋白)중 분자량 72K 또는 125K 달톤의 항원(抗原)에 대응하는 항체(抗體)였으며, 94K 달톤의 항원(抗原)에 대응하는 단(單)클론성 항체(抗體)는 중화력(中和力)이 인정되지 않았다. 한편 1종의 교차반응성(交叉反應性) 항체(抗體)는 분자량 100K 달톤의 IBRV 항원(抗原)과 40K의 Pseudorabies virus 항원(抗原)에 대응하는 항체(抗體)로 밝혀졌다. 생산된 항체(抗體)중 중화력(中和力)이 있고 IBRV 항원(抗原)의 72K 달톤 단백질(蛋白質)에 대응하는 7-C-2 항체(抗體)를 이용하여 야외분리주(野外分離株) IBRV의 항원(抗原) 동정(同定)이 가능(可能)하였다.